Member Info for chester18

The opening sentence should be :

The Scancell submission may not be ..... 'revealed' ....... until a few days before the conference starts.

Chester.

The Scancell submission may not be until a few days before the conference starts. Interestingly here is the list of Categories Allowed.

Abstract Categories : -

With a little help from my friends: innate immune cells and stromal cells in the tumor microenvironment.

Deranged T and B cells within the tumor microenvironment.

Lung cancer at the forefront of cancer immunotherapy.

Harnessing immunotherapy against breast cancer ****

The earlier the better: neoadjuvant immunotherapy against cancer.

Technologies, technologies, technologies: we need more.

How to overcome resistance of poorly sensitive tumors to immunotherapy.

What’s next in the pipeline of melanoma treatment ****

Metabolic barriers to cancer immunotherapy.

Determinants of response to immunotherapy.

What we can learn from hematologic malignancies.

Bang on target: modulating the microbiota to improve cancer immunotherapy.

Cellular therapies: arming immune cells ****

I have **** the three most interesting headings for our trials.

This conference actually offers Scancell some really useful topics that may help them in their research into how to overcome situations where the initial positive effect of Moditope is slowed or stopped by the cancer tumours ability to resist or mutate sufficiently to prevent 100% eradication.

This conference looks to be perfectly timed for Scancell.

Chester.

Ciaskin

That is a very astute question.

In some cases I would expect the answer to be yes.

Chester.

Hi crumbs

We can now see that Moditope does not obliterate cancer tumours that are at such a mature stage. Patients that have undergone Chemo and their tumour has not been vanquished probably end up with a very hard to treat biome. Moditope in this setting does not have the range or scope to eradicate a person's individual tumour.

As this trial progresses Scancell will discover where it is most effective.

My take is that we had to engage at the most difficult end of the spectrum to be able to find enough patients willing to take part in our trial. There are some very important lessons being learnt and I back Lindy and her team to navigate their way towards the correct position for Modi1. It may end up being in earlier stages or in combination with CPI's.

It may even be in combo with Modi2. You never know.

Chester.

Thank you both for your responses.

I realise these mammoth acquisitions do take time to come together. It would seem from you have said the vote will be within the next four to six weeks.

All the best

Chester.

I've not posted here for quite some time. Still hold a few 100k's of shares

Please excuse my ignorance but when will Newcrest shareholders actually get he chance to vote on the proposed Newmont Takeover.

I'm aware it's in September but is there a specific date ?

Chester.

Yes, and Covidity, which is now becoming more viable as Covid mutates further and further away from the original RNA vaccines.

Chester.

When the Macmillan story broke in Feb 2023 the SP rose on all the positive hype and then declined over time. This is now an opportunity for some negative hype.

We are two weeks out from CICON Milan and we have been told info about SCIB1 and Modi1 will be shared by Scancell.

This reaction to the Macmillan website post is understandable but this knee jerk response is as if Scancell don't know and we've found out before the company.

I hope for all those that have sold out that positive news doesn't drop on GenMab, or AvidiMab or GlyMab or BionTech and leave them scrambling back in.

Can we all please remember that Moditope cleared early, single biome tumours in mouse models. Our current patients have mature and very complex tumours and yet Moditope still is having an effect.

ModiFY is a work in progress and only Scancell know the scientific truth of its progress.

Chester

Hi C11

You are correct but my comment about October being the time for the SCIB1 read out is also correct. That Business Update RNS in July says 'SCOPE Trial to have Top Line Read Out Q4 2023'.

Q4 is Oct, Nov and Dec. Some interesting data will be announced at the Milan Conference but according to that RNS it won't be a full TopLine Data reveal.

We will know what was actually meant in just a few weeks time.

All the best

Chester.

September will see the arrival of our new Business Development Manager. Scancell have shown patience in getting their preferred choice for that role.

CICON Conference in Milan 20th to 22nd Sept.

October :

World Vaccine Conference 16th to 19th October. This is around the time we will start to hear how SCIB1- SCOPE Trial has progressed. Maybe some indication of when iSCIB1+ will be approved.

The Annual Results for year ending 30th April 2023 should be RNS'ed by the end of October with the date of the 2023 AGM confirmed.

Between the World Vaccine Conference and the year end accounts we should also have some details on the ModiFY trial progress.

Prior to the AGM ( late Nov ) we need to also hear what has happened to Modi2 and our potential TCB Antibdy. At the AGM if we have not heard beforehand we need full updates on, GenMab progress and potential of that deal moving to the next Milestone, BionTech and the ModiFY Activated 'T' Cells they wanted and have probably been supplied with already, what levels of intest have seen in our other Platforms, namely AvidiMab and GlyMabs.

Next 2 / 3 months are going to be very revealing and should be very positive for the SP, in my humble opinion.

Chester.

I would imagine that Sath met all our required criteria. He has gain plenty of experience in his career so far.

Most importantly he will have enough experience to suit Scancell and his wage will be in line with what we can currently afford.

Chester.

Hi Burble

Following that train of thought I would suggest that Scib1 is working well in the the patients that currently fit the correct profile. As we know this is a sub-set of melanoma patients.

The move to iSCIB+ triples the number of potential patients which means with the right data results it will be commercially extremely valuable.

The 'would' in that RNS says that a suitor has very possibly laid their cards in the table given iSCIB+ brings in the right level of positive data.

The sooner we are informed that we have approval to move the SCOPE trial to the newer version the better.

Chester.

Hi LochinvarLass

All we can go on is that for the last three years the AGM has been around the 3rd week of November.

We won't know for sure until its announced but Monday 20th November is my guess.

Hope you are keeping well.

Chester.

For 'episodes ' please substitute 'epitopes'......

Hi Rookie1

Scib1 trial which is called 'SCOPE' has been progressing quietly in the background while all attention has been on Modi1, 'ModiFY Trial'.

If you have not closely followed the journey there are three things to note about SCIB1:

A) It is now a needle free injection using PharmaJet technology.

B ) We have been told there will be a full Data Readout by the end of the year, probably before the AGM in late November.

C ) SCIB1 is to be enhanced very soon with additional episodes and Scancell 'AvidiMab' platform that increases the potential binding of the drug to the target. It will become iSCIB+.

The SCOPE trial has been moving forward and is very close to enrolling the target number of trial patients. Another positive is the increase overtime of the number of clinical sites that have signed up to be part of the trial.

Our CEO said if you like SCIB1 you will love iSCIB+.

Hope that is a helpful starter for you.

Chester.

Thank you TF

August is holiday season so it can be very slow news wise. It would be excellent to have something to happen prior to the 19th of September but Scancell may have good reasons to delay any news until they are at those conferences.

I'm staying very positive and hoping that GenMab are progressing towards a phase one trial with our Glymab target 🤞🤞

Thank you TF

August is holiday season so it can be very slow news wise. It would be excellent to have something to happen prior to the 19th of September but Scancell may have good reasons to delay any news until they are at those conferences.

I'm staying very positive and hoping that GenMab are progressing towards a phase one trial with our Glymab target 🤞🤞

I've just listened to that Pod Cast. It just shows how difficult it is to convince Large Pharma and Clinicians to move from the tried and tested 'known' to the new 'unknown', without solid data.

Mid 1990's presenting a Checkpoint Inhibitor to 30 or so at a conference and being told that changing the tumour micro enviroment was bunkum and what was needed were better drugs.

Now 25 years later Immuno-Oncology the biggest rooms at conferences with 3,000 to 4,000 in attendance.

Our ModiFY Trial has had to begin by seeing if we can make a difference to the most poorly of cancer patients. The reason is partly due to the successful adoption of Checkpoint Inhibitors in earlier patients.

Both of Scancells Trials are progressing positively and its only a matter of time before we get those fuller trial readouts.

ModiFY could have a 6 month update later this month 🤞and the Scope Trial update is promised by the end off this year.

Nobody enjoys newsless periods of time but the September Conferences will be here really soon.

Chester.

There was nothing wrong with the Austin Allegro, I started one once.........🤣

SCIB1 Scope Trial :

Progressing well, soon to transit to iSCIB+.

Promise of Full Update on Scope Trial by December.

iSCIB1+, first data mid to late 2024.

GlyMabs / GenMab deal, we are already £5m up and we have a very good chance of the next Milestone payment. The deal is 10 months old in August plus we are told, more deals are being discussed.

Finances are solid until next May / June, plenty of time to get a few deals over the line. We can concern ourselves with that next March / April, if nothing has generated some spending money.

Modi1 'mono' : (Safe and No major Toxicity issues)

Head & Neck ( regression seen in at least 1 patient )👍

Ovarian ( 44% of patients treated having stable disease ) 👍

Renal 👍

TNBC ( late stage ) needs help of CPI plus at earlier stage intervention we may see a more significant result.

Modi1 + CPI :

Head & Neck ( regression seen in first patient ) 👍

Renal ( TBA ) but moving forward 👍

Ovarian and TNBC both need a Pharma Partner to promote a Modi1 + CPI Trial.

As trials go there are a lot of positive results across Scope and ModiFY.

Chester.